Clinical Trial - Trial jRCT2031200367
Access comprehensive clinical trial information for jRCT2031200367 through Pure Global AI's free database. This phase not specified trial is sponsored by Amgen K.K. and is currently Completed. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
jRCT2031200367
Completed
Trial Details
Japan Registry Clinical Trial • jRCT2031200367
Untitled Trial
A Double blind, Randomized, Placebo controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Study Focus
Interventional
Sponsor & Location
Amgen K.K.
Australia;Canada;Iceland;United States of America;Denmark;Netherlands
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Cardiovascular disease, unspecified
Hypertensive heart disease
Heart disease, unspecified
Atherosclerotic cardiovascular disease, so described
Atherosclerotic heart disease
Data Source
Japan Registry Clinical Trial
jRCT2031200367
Non-Device Trial